Advances in management of high-risk gestational trophoblastic tumors

John Robert Lurain III*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Multimodality therapy with combination chemotherapy employing etoposide, high-dose methotrexate, actinomycin D, cyclophosphamide and vincristine and adjuvant radiotherapy and surgery, when indicated, has resulted in cure rates of 80-90% in patients with high-risk metastatic gestational trophoblastic tumors. However, 25-30% of high-risk patients will have an incomplete response to first-line chemotherapy or will relapse from remission. Most of these patients will have a clinicopathologic diagnosis of choriocarcinoma, multiple metastases to sites other than the lung and vagina, and failed or inappropriate previous chemotherapy, resulting in very high World Health Organization scores. Salvage chemotherapy with cisplatin/etoposide, usually in conjunction with bleomycin or ifosfamide, as well as surgical resection of sites of resistant disease in selected patients, will result in a cure for most patients. Colony-stimulating factors should be used to prevent treatment delays and dose reductions. Newer anticancer agents, such as paclitaxel and gemcitibine, and high-dose chemotherapy with or without autologous bone marrow transplantation or peripheral blood stem cell support may play a role in the future management of selected patients.

Original languageEnglish (US)
Pages (from-to)451-459
Number of pages9
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Issue number6
StatePublished - Jan 1 2002


  • Choriocarcinoma
  • Combination chemotherapy
  • Trophoblastic tumor

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Advances in management of high-risk gestational trophoblastic tumors'. Together they form a unique fingerprint.

Cite this